非小细胞肺癌分子靶向治疗的毒性反应研究进展

Toxicity of molecular targeted therapy in non-small cell lung cancer

近年来,非小细胞肺癌的分子靶向治疗成为研究的热点,分子靶向治疗药物主要包括表皮生长因子受体(epidermal growth factor receptor,EGFR)单克隆抗体、血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)单克隆抗体、表皮生长因子受体酪氨酸激酶抑制剂等。这些药物在临床上都取得了一定的疗效,同时也出现了皮疹、腹泻、高血压等若干毒性反应,还有一些新药,如索拉非尼、舒尼替尼、伏立诺他、范得它尼等,都有相关的毒性反应。分子靶向治疗毒性反应严重影响了患者的生活质量和服药的依从性。本文就非小细胞肺癌分子靶向药物的毒性反应及处理措施作一综述。

Molecular targeted therapy has recently become a focus of study for non-small cell lung cancer.The drugs for molecular targeted therapy mainly include monoclonal antibodies against the epidermal growth factor receptor（EGFR）,against vascular endothelial growth factor receptor（VEGFR）,and EGFR tyrosine kinase inhibitors.These drugs have achieved positive outcomes in clinic,but they also have toxic effects such as rash,diarrhea,and hypertension.Some new agents in clinical development,such as sorafenib,sunitinib,vorinostat,vandetanib,also showed toxic effects,which greatly influence the patients quality of life and reduce the compliance for the drugs.This paper reviews the toxicities and the managements of molecular targeted drugs during treatment of non-small cell lung cancer.